Meenakshi Prabhune, PhD | Feb 23, 2024 | 10 min read
With deep learning methods revolutionizing life sciences, researchers bet on de novo proteins and cell mapping models to deliver customized precision medicines.
Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.
Research traces the evolution of a gene variant that reduces the risk of Alzheimer’s disease, finding that it originally evolved in response to infectious bacteria.
Early reports that Omicron causes less-severe disease than Delta seem to be borne out, but it’s not yet clear to what extent that’s due to the variant itself versus the populations it’s infecting.